Introduction:
Type 2 diabetes mellitus(DM) happens when the body cannoteffectively use the insulin it produces. Formerly, it was called non-insulin dependent or adult onset diabetes mellitus as because, for many years it was seen only in adults.In type 1 diabetes mellitus, the body does not produce insulin and it is usually diagnosed in children and young adults. Recently,type 2 diabetes mellitushas increasingly been reported in children and adolescents, so much so that in some parts of the world type 2 diabetes has become the main type of diabetes in children. The global rise of childhood obesity and physical inactivity is widely believed to play a crucial role 1 . Currently, more than 200 children and adolescents develop the disease every day worldwide 2 . But healthy eating and lifestyle habits are a strong defense against the disease.
Risk factors and PathophysiologyofType 2 DM:
Type 2 DMis a complex metabolic disorder of heterogeneous etiology with social, behavioral, and environmental risk factors unmasking the effects of genetic susceptibility 3 . There is a strong hereditary component of the disease. The major risk factors of type 2 DM in children are: obesity and inactivity, family history of type 2 DM, age of 12-16 years, maternal gestational diabetes or type 2 diabetes, not breast feeding during infancy and ethnicity. Other factors that appear to increase risk include poor fetal growth, low birth weight and high birth weight 4 . Impaired glucose homeostasis is the key mechanism in type 2 DM and it depends on the balance between insulin secretion by the pancreatic â-cells and insulin action. The mean age range of onset of type 2 diabetes in youths coincides with the relative insulin resistance that occurs during pubertal development, resulting in hyper-insulinemia and play a major role in the development of type 2 DM in children and adolescents. The adverse effect of obesity on glucose metabolismis evident early in childhood. Obese children arehyper-insulinemicand have approximately 40% lower insulinstimulatedglucose metabolism compared with non-obesechildren 5 .
Epidemiology of Type 2 DM in children and adolescents:
Type 2 DM in youth appears to be emerging as a seriousclinical issue. It's prevalence in the United States (USA) is approximately12:100000, while it is still rare in Europe 6 (approx.,2.5:100000). In Bangladesh the exact prevalenceof Type 2 DM is not known. But in a studyamong 2152 students volunteers inBangladesh, Abu Sayeedet al 7 . observedthat the prevalence of type 2 DM and impaired fasting glucose (IFG)appears to be1.8% and 3.4% respectively. The majority of USA young peoplediagnosed with type 2 diabetes are found inspecific ethnic subgroups such as AfricanAmerican,Hispanic, Asian/Pacific Islanders and American Indiansbeing highest in Pima Indians (22.3/ 1000 in 10-14 yearold children). Furthermore, the great majorityof the children are obese. Screening studies in obeseadolescents have reported a prevalence of 0.4% up to1% of type 2 diabetes in obese children e" 12years 8 .
Clinical presentationof Type 2 DM:
The presentation of type 2 DMin children and adolescents varies according to the disease stage. Early in the disease, before diabetes diagnostic criteria are met, insulin resistance predominates with compensatory high insulin secretion, resulting in normoglycemiaand the patient likely to be asymptomatic 9 . At this stage, the disease may only be detected by abnormal blood glucoseconcentrations identified during screening. Obesity is the hallmark of type 2 diabetes in children and adolescents.Most children are obese orextremely obese at diagnosis and present with glycosuriawithout ketonuria, absent or mild polyuria and polydipsia,and little or no weight loss. In its severest form, the child presents with polyuria,polydipsia, and weight loss. Up to 33% in particularethnic groups have ketonuria at diagnosis and 5%-25%ketoacidosis at presentation 10 11 .Type 2 diabetic children and adolescents may represent a form of earlyonset latent autoimmune diabetes mellitus similar to that described in adults (LADA). These Patients with LADA share insulin resistance with that of type 2 diabetes mellitus patients but display a more severe defect in â-cell capacity 12 . Following the terminology 'latent autoimmune diabetes mellitus in adulthood, LADA', the non-insulin dependent diabetic children and adolescents with â-cell autoantibodies could be named 'latent autoimmune diabetes mellitus in youth' (LADY) 13 . Double diabetes mellitus or type 1.5 diabetes mellitus are other proposed names for this entity 13 . Maturity-onset of diabetes mellitus of the young(MODY) is another rare form of diabetes mellitus inchildren that includes several disorders caused by monogenicdefects in â-cell function 14 . MODY 2 and MODY 3 (defect in glucokinase and HNF1á respectively) are themost frequent types of MODY. Patients with MODYhave a dominant genetic traits, usually are nonobese andhave low fasting insulin levels. Recent studies suggestthat the clinical presentation of MODY is broad, rangingfrom asymptomatic hyperglycemia to a severe acutepresentation 13 .
Diagnostic criteria for Type 2 Diabetes Mellitus:
Diagnosis of type 2 Diabetes Mellitus in children and adolescents can be made on the basis ofAmerican Diabetic Association(ADA)revised diagnostic criteria (Table1) 15 or any other diagnostic criteria. In the absence of unequivocal hyperglycemia, random, fasting or twohoursblood sample should be confirmed by repeat testing.Other tests may be necessary in difficult cases for diagnosis of type of DM, such as fasting insulin or C-peptide determination and occasionally, β-cell autoantibodies measurements. C-peptide levels are elevated in individuals with type 2 diabetes mellitus in contrast to patients with type 1diabetes mellitus or MODY diabetes. 16 .It is found that unrecognized hyperglycemiacontributes to both microvascular and macrovascular risk in later life 17 . However, at the present time, a general screening for type 2 DM in youth is unlikely to be costeffective and so a targeted screening is necessary. The ADA recommends a screening in overweight children and adolescents at onset of puberty in high risk patients (Table 2) . Screening test should be performed every 2 years starting at the age of 10 years or at onset of puberty. It should be done by testing fasting glucose or oGTT 18 . Overweight (BMI > 90 percentile) plus one of the following risk factors:
• Family history of type 2 DM in 1 0 or 2 0 relative;
• Race/ethnicity (Asian, American Indian, AfricaAmericans, Hispanics);
• Signs of insulin resistance; or conditions associated with insulin resistancesuch as acanthosisnigricans, hypertension, dyslipidemia, polycystic ovarian syndrome (PCOS);
• Extreme obesity (BMI > 99.5 percentile).
Complications of Type 2 Diabetes Mellitus:
The chronic complications of type 2 DM in children and adolescents are macrovasculardiseases like accelerated developmentof cardiovascular disease leading to stroke andmyocardial infarction, and microvascular diseases likenephropathy, retinopathy and neuropathy leading toend-stage renal disease, loss of visual acuity, and limbamputations. Microvascular disease is the hallmark of hyperglycemia diagnosed at a younger age. As becausethe complications of DM are related to the duration of disease itself, risksof complications more common in children and adolescents as compared to adult diabetics 19 .All of these complications contribute tothe excess morbidity and mortality in individuals withdiabetes mellitus.Youngpeople with type 2 DM appear to be at amuch higher risk of developing early diabetes associated complications than those with type 1 diabetesMellitus 20 . This higher level of risk does not appear to berelated to overall levels of glycemic control or durationof disease but to occurrence of hypertension and dyslipidemia.
Management of Type 2 Diabetes Mellitus:
The idealgoalof management( 22 . Despite of severe manifestation, initial management of obese children and adolescents with type 2 DM should consist of behavior modification strategies for lifestyle change such as decreasing high-caloric high-fat food choice and sedentary behavior, while increasing physical activity. Lifestyle changes should not be imposed and selfmotivation is necessary 23 .Treatmentoptions of type 2 DM include: Diet: Balanced macronutrient diets at 900 to 1200 kcal per day are associated with both short and long-term (e"1 year) improvements in weight status and body composition in children 6 to 12 years of age 24 .These calorie management are to be incorporated with lifestyle changes, including increased activity and medication. Restrictions of no less than 1200 kcal per day in adolescents 13 to 18years old result in improved weight status and body composition 25 .
Physical activity:It is an integral part of weight management for prevention and treatment of type 2DM.
Children and adolescents are encouraged to engage in 'moderate-to-vigorous' exercise for at least 60 minutes daily and to limit non-academic 'screen time' to less than 2 hours a day. Screen time contributes to a sedentary lifestyle, especially when the child or adolescent eats while watching television or playing computer games 26 .
Patients education:All children with type 2 diabetes mellitus should receive comprehensive self-management education which include teaching self-monitoring of blood glucose,performed as needed and during periods of acute illness or when symptoms of hyper-or hypoglycemia occur 27 .
Pharmacological treatment:If treatment goal with nutrition education and exercise is not met, pharmacological therapy is indicated. Metformin andinsulin are the only anti-diabetic agentscurrentlyrecommended for use inchildren. Thiazolidinediones andincretins are occasionally used inadolescents younger than 18 years 28 .Metformin, a biguanide, is the most appropriatestarting point for pharmacological treatmentin children with type 2 diabetes mellitus if insulin therapy is not indicated. The effectivenesshas been proven for adolescents in clinical trials. Metformin decreases hepatic glucoseoutput and enhances primarily hepatic and also muscleinsulin sensitivity without a direct effect on â-cell function.It has the advantage of weight reduction,decrease in lipids without the risk of hypoglycemia.Because of concerns about lactic acidosis metformin iscontraindicated in patients with impaired renal function and should be discontinued with the administration ofradiocontrast material or hypocaloric diet. Metforminshould not be used in patients with known hypoxemicconditions, severe infection, hepatic disease, or alcoholabuse. The most common side effects of metformin aregastrointestinal disturbances. The dose of metforminshould be increased up to 2 gm in split doses, unless thereare gastrointestinal side effects. Metformin has a goodsafety record, but should not be given if there is anydoubt at all about the nature of diagnosis.Rosiglitazone, a thiazolidinedione hasbeen studied in some randomized trial in adolescents comparedto lifestyle intervention and metformin and found some effects. However,rosiglitazone has been withdrawn from the market due toits side effects and is not available any more 13 .
If monotherapy with metformin is not successful over a reasonable period of time (3-6 months), insulin treatment will often be the only feasible way of controlling hyperglycemia. There is no specific contraindication to insulin in children. Any type of insulin and analogs can be used. Insulin regimes should be adopted that are carefully tailored to lifestyle such as bedtime insulin alone, twice-a-day insulin or multidose insulin regimes 13 .Basal insulin is provided through either the use of long acting, relatively peak-free insulin by needle or via an insulin pump. Bolus insulin doses are given at meal-time, using one of the rapid-acting insulin analogs. The bolus dose is calculated by using a correction algorithm for the premeal blood sugar concentration as well as a "carb ratio," in which 1 unit of a rapid-acting insulin analog is given for "X" grams of carbohydrates ingested (For example, see Table 4 ) 15 .
Table -IV

Calculation of Basal Bolus Insulin Regimen 15
• If an adolescent has a blood glucose of 250 mg/dL, is to consume a meal containing 60 gm of carbohydrates, with a carbohydrate ratio of 1:10 and an assigned correction dose of 1:25>125 the mealtime bolus dose of insulin would be as follows: 60 gm/10 =6 units rapid-acting insulin for meal plus (250-125)/25 = 125/25 = 5 units rapid-acting insulin for correction; Thus, total bolus insulin coverage at mealtime is: 11 Units (6 + 5) • Note: Insulin sensitivity-25; Target blood glucose level-125mg/dl,'carb ratio'-10.
Monitoring of Diabetes Mellitus and treatment of complications:
All children and adolescents with newly diagnosed type 2 DM, regardless of prescribed treatment plan, should perform finger-stick blood glucose monitoring before meals and at bedtime until reasonable metabolic control is achieved 29 . Once blood glucose concentrations are at target levels, the frequency of monitoring can be modified depending on the medication used, the regimen's intensity, and the patient's metabolic control. 
Conclusion:
Type 2 diabetes mellitus is emerging as a new clinical problem within pediatric practice. Clinicians should be aware of the frequent mild or asymptomatic manifestation of type 2 diabetes mellitus in childhood. Therefore, a screening seems meaningful especially in high risk groups such as children and adolescents with obesity, relatives with type 2 diabetes mellitus, and clinical features of insulin resistance. Emphasis should be given on early diagnosis and comprehensive management plan to avoid grave consequences of it in early part of life. All efforts should be given on prevention of type 2 DM such as, healthy eating, physical activity, and modest weight reduction. Collaborative efforts from all corners of the modern society can efficiently combat against this emerging disease.
